The combination of meclorethamine, vincristine, prednisolone, and procarbazine is used for the treatment of patients with:
*MOPP, the combination regimen of meclorethamine, vincristine (Oncovin), prednisone, and procarbazine, is often alternated with the ABVD regimen [doxorubicin (Adriamycin), bleomycin, vincristine, and dacarbazine in the treatment of patients with Hodgkin's disease, These regimens are based on the use of drugs with different mechanisms of action and different toxicities, so that the cancer cells are attacked at different sites of action, and the collective toxicity is not directed toward one organ system. Mechlorethamine is a nitrogen mustard alkylating agent, vincristine is a mitotic spindle poison, prednisone is a glucocoicoid with lymphotoxic effects, and procarbazine has multiple actions directed azainst nucleic acids and proteins. Vincristine and prednisone produce less bone marrow suppression than alkylating agents and antimetabolites.
Acute lymphocytic leukemia
Chronic lymphocytic leukemia
Hodgkin's disease
Acute myelocytic leukemia